Patients Treated for SCID (1968-Present)

Related Clinical Trial
A Study to Assess a Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Allografts Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus cliniMACs HUD for T Cell Depletion Cord Blood Stem Cell Transplantation Study (COBLT) Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products Lentiviral Gene Therapy for Adenosine Deaminase (ADA) Deficiency Genetic Basis of Immunodeficiency IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency Sirolimus Prophylaxis for aGVHD in TME SCID Study Through Imaging of Visceral Lymphoid Organs in Patients With SCID Who Have Recieved Bone Marrow Allograft Influences on Female Adolescents’ Decisions Regarding Testing for Carrier Status of XSCID Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant EZN-2279 in Patients With ADA-SCID AMG191 Conditioning/CD34+CD90 Stem Cell Transplant Study for SCID Patients Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1) Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population Gene Transfer for Severe Combined Immunodeficiency, X-linked (SCID-X1) Using a Self-inactivating (SIN) Gammaretroviral Vector Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders Stem Cell Gene Therapy to Treat X-Linked Severe Combined Immunodeficiency (XSCID) Patients Treated for SCID (1968-Present) Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China Gene Therapy for ADA-SCID MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID Transplantation of Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim Natural History Study of SCID Disorders Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency SCID Bu/Flu/ATG Study With T Cell Depletion Generalized Neonatal Screening of Severe Combined Immunodeficiencies Neonatal Screening of Severe Combined Immunodeficiencies Gene Therapy for X-linked Severe Combined Immunodeficiency An Observational LTFU Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for ADA-SCID Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID) Registry Study of Revcovi Treatment in Patients With ADA-SCID Multi-center Clinical Study of Cord Blood Stem Cell Transplantation for SCID

Brief Title

Patients Treated for SCID (1968-Present)

Official Title

A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)

Brief Summary

      Individuals with a past diagnosis of severe combined immune deficiency (including many cases
      of "leaky SCID", Omenn syndrome, and reticular dysgenesis) who have undergone blood and
      marrow transplant, gene therapy, or enzyme replacement in the past may be eligible for this
      study. The purpose of study is to look backwards at what has already been done in the. Over
      800 patients with SCID are expected to be enrolled, making this one of the largest studies
      ever to describe outcomes for patients with SCID treated at many different hospitals around
      North America.

Detailed Description

      One of the most important components of this study is the "cross sectional" aspect. Patients
      who have received their treatments (BMT, gene therapy, enzyme replacement) many years ago are
      asked to come back to the hospital where they were treated. During this visit, additional
      research bloodwork is drawn, and information is gathered regarding long-term transplant
      outcomes such as infections, graft-versus-host disease, autoimmune diseases, and quality of
      life. This will allow PIDTC researchers to better understand long-term outcomes from
      procedures that occurred many years ago (sometimes over 30 years ago). This will help
      researchers to best design new treatments and clinical trials in the future for children with

Study Type


Primary Outcome

Retrospective Study - Part 1

Secondary Outcome

 Retrospective Study Part 1



Study Arms / Comparison Groups

 Stratum A -Typical SCID
Description:  Typical Severe Combined Immunodeficiency (SCID), Adenosine Deaminase-Deficient ADA SCID, and X-linked SCID (XSCID) who received a transplant


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment


Start Date

May 15, 2011

Completion Date

August 2023

Primary Completion Date

August 2023

Eligibility Criteria

        Inclusion Criteria:

        Strata A, B, and C (Part 1 - Retrospective Study)-

          -  Individuals with Severe Combined Immune Deficiency (SCID) diagnosis who:

             --were treated at a location participating in this consortium from 1968 until present,

             --are not enrolled in RDCRN PIDTC-6901 ( ID: NCT01186913).

          -  Subjects who received HCT/GT/ERT prior to the present date are eligible for the
             retrospective study. The enrollment criteria for subjects who died prior to definitive
             therapy are the same as for Strata A, B and C.

        Stratum A, Typical SCID:

          -  Individuals who meet the following inclusion criteria and who received HCT are
             eligible for enrollment into Stratum A of the study:

               -  Absence or very low number of T cells (CD3 T cells < 300/microliter), and no or
                  very low T cell function (< 10% of lower limit of normal) as measured by response
                  to phytohemagglutinin (PHA) or cells of maternal origin present.

               -  If maternal cells are present but the patient does not meet criteria for very low
                  T cell function as defined, the assigned reviewers for the potential subject, and
                  if necessary, the full PID-SCID RP will review the laboratory report to determine
                  if criteria of maternal engraftment are met for Protocol 6902.

               -  Laboratory report of testing for maternal engraftment is required, for evaluation
                  by the PID-SCID RP.

        Stratum B, Leaky SCID, Omenn Syndrome, Reticular Dysgenesis:

        Individuals who meet the following criteria are eligible for enrollment into Stratum B of
        the study:

        Leaky SCID-

          -  Maternal lymphocytes tested for and not detected and,

          -  Either one or both of the following (a,b):

             a) < 50% of lower limit of normal T cell function (as measured by response to PHA OR <
             50% of lower limit of normal T cell function as measured by response to CD3/CD28
             antibody, b) Absent or < 30% lower limit of normal proliferative responses to candida
             and tetanus toxoid antigens postvaccination or exposure,

          -  AND at least one of the following (a through e):

               1. Reduced number of CD3 T cells,

               2. > 80% of CD3+ or CD4 T cells are CD45RO+,

          -  AND/OR >80% of CD3+ or CD4+ T cells are,CD62L negative,

          -  AND/OR >50% of CD3+ or CD4+ T cells express HLA-DR (at < 4 years of age),

          -  AND/OR are oligoclonal T cells. c) Hypomorphic mutation in IL2RG in a male, or
             homozygous hypomorphic mutation or compound heterozygosity with at least one
             hypomorphic mutation in an autosomal SCID-causing gene.

             d) Low TRECs and/or the percentage of CD4+/45RA+/CD31+ or CD4+/45RA+/CD62L+ cells is
             below the lower limit of normal.

             e) Functional testing in vitro supporting impaired, but not absent, activity of the
             mutant protein,

               -  AND does not meet criteria for Omenn Syndrome,

               -  AND does not have known selective loss of lymphocytes, Ataxia- Telangiectasia, or
                  congenital heart defect associated with lymphopenia, unless a SCID genotype is
                  also present.

        Omenn Syndrome (OS):

          -  Generalized skin rash,

          -  Maternal engraftment tested for and not detected,

          -  Absent or low (up to 30% of normal) T cell proliferation to antigens to which the
             patient has been exposed.

          -  If the proliferation to antigen was not performed, but at least 4 of the following 10
             supportive criteria, at least one of which must be among those marked with an asterisk
             (*) are present, the patient is eligible: hepatomegaly; splenomegaly; lymphadenopathy;
             elevated IgE; elevated absolute eosinophil count; *oligoclonal T cells measured by
             CDR3 length or flow cytometry >80% of CD4+ T cells are CD45RO+ ;*proliferation to PHA
             is reduced <50% of lower limit of normal or SI <30; *proliferative response in mixed
             leukocyte reaction is reduced to increment cpm < 20% or SI <20; hypomorphic mutation
             to SCID causing gene; low TRECs and/or percentage of CD 4+/ RA+/CD31+; or
             CD4+/RA+/CD62L+ cells below the lower limit of normal.

        Reticular Dysgenesis (RD):

          -  Absence or very low number of T cells (CD3 T cells <300/microliter),

          -  No or very low (<10% of lower limit of normal) T cell function (as measured by
             response to phytohemagglutinin (PHA),

          -  Severe congenital neutropenia (absolute neutrophil count <200/microliter),

          -  AND at least one of the following:

               -  Sensorineural deafness and/or absence of granulopoiesis at bone marrow
                  examination and/or a deleterious AK2 mutation,

               -  absence of granulopoiesis on bone marrow examination; a pathogenic mutation in
                  the adenylate kinase 2 (AK2) gene identified.

        Stratum C, SCID with Non-HCT Treatments:

        -Individuals who meet the following criteria and were treated with PEG-ADA or gene therapy
        with autologous modified cells are eligible for enrollment into Stratum C (SCID with
        non-HCT treatments) of the study-

        - Any SCID patient previously treated with a thymus transplant (includes intention to treat
        with HCT, as well as PEG-ADA ERT or gene therapy).

        Strata A, B, and C (Part 2 - Cross-Sectional Study):

        Patient inclusion criteria for the cross sectional study: Eligibility for Strata A, B and C
        are the same as for the retrospective study except that all the patients in the
        cross-sectional study are currently surviving and are at least 2 years post the most recent
        class of therapy.

        Exclusion Criteria:

        Parts 1 and 2 - Retrospective and Cross-Sectional Studies -

          -  Lack of appropriate testing to rule out HIV infection after 1997 (p24 antigen or more
             sensitive) or other cause of secondary immunodeficiency,

          -  Presence of DiGeorge syndrome,

          -  Most patients with other PIDs such as nucleoside phosphorylase deficiency, ZAP70
             deficiency, CD40 ligand deficiency, NEMO deficiency, XLP, cartilage hair hypoplasia or
             ataxia telangiectasia will not meet the inclusion criteria for Stratum A, B, or C
             above; however, a patient with one of the above may meet the inclusion criteria for
             Stratum B and if so will be included-

               -  MHC Class I and MHC Class II antigen deficiency are excluded,

               -  Metabolic conditions that imitate SCID or related disorders such as folate
                  transporter deficiency, severe zinc deficiency, transcobalamin deficiency.




N/A - N/A

Accepts Healthy Volunteers



Elie Haddad, MD, PhD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)


 Primary Immune Deficiency Treatment Consortium (PIDTC)

Study Sponsor

Elie Haddad, MD, PhD, Study Chair, University of Montréal, CHU Sainte-Justine

Verification Date

November 2020